Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

Calls for ‘fat tax’ to be introduced on junk food to cut childhood obesity

Expert groups quoted in a report suggest solutions including an ‘excess profits’ tax on products with a high sugar and salt content

The Independent UK

Bowel cancer cases in young people rising sharply in England, study finds

Experts believe poor diet, more ultra-processed foods, obesity and a lack of exercise are playing a role.

The Independent UK

2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Life expectancy in U.S. could stall by 2050 because America is getting too fat, physicians warn

Rising rates of obesity and drug use deaths are forecast to contribute to future life expectancy

The Independent UK

WATCH: Vince Papale talks tackling obesity, ROCKY-Run, and Eagles Super Bowl hopes

Vince Papale sat down with The Eagles Wire to talk about how he tackled obesity, his beautiful wife Janet Kent, his talented son and UFL receiver Vinny Papale, and whether Nick Sirianni's team has what it takes to win a Super Bowl.

USA Today Sports Media Group

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Fortune

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk

Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.

Investors Business Daily

Sugary porridge and crumpets among food products in anti-obesity advertising ban

The ban, which will come into effect in October 2025, will mean ‘unhealthy’ products cannot be advertised before the watershed.

Evening Standard

Porridge and crumpets among list of breakfast foods in anti-obesity ban

The ban will come into effect in October 2025 and includes croissants and protein bars

The Independent UK

Junk food advert ban ‘will prevent 20,000 cases of childhood obesity’

The ban will come into force next October

The Independent UK

Junk food ad ban ‘will prevent an estimated 20,000 cases of childhood obesity’

The Government confirmed the laying of secondary legislation for the ban on Tuesday.

Evening Standard

Jamie Oliver launches campaign to target child obesity at London primary schools

Evening Standard

France's proposed new sugar tax could transform the biggest food companies—will the consumer pay the price?

In the fight against obesity and the need to raise revenue for a seriously impoverished economy, one policy idea is to tax these sugary, highly processed products.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

LiveScience

Ozempic-like drugs may treat alcohol addiction, study finds

A study using Swedish patient data found anti-obesity drugs were linked with fewer hospitalizations related to alcohol use, adding to a body of work suggesting these drugs could potentially be used to manage addiction.

LiveScience

Fat cells have a 'memory' of obesity, study finds

Most people who lose weight through dieting will see it creep back up, leading to a cycle of "yo-yo dieting" that's hard on the body. A new study suggests fat cells keep a memory of previous weight gain, which may help to explain why this happens.

The Conversation

Why some people don’t lose weight with Wegovy

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% of their body weight. But the drugs don’t work for everyone.

The Conversation

208 million Americans are classified as obese or overweight, according to new study synthesizing 132 data sources

Nearly half of adolescents and three-quarters of adults in the U.S. were classified as being clinically overweight or obese in 2021. The rates have more than doubled compared with 1990.

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

Biden Administration Proposes Expanded Coverage For Anti-Obesity Drugs

Biden administration proposes expanding coverage for anti-obesity drugs to millions, potentially reducing costs for vulnerable populations.

Fortune

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Roll Call

White House rule would expand coverage of anti-obesity drugs - Roll Call

It’s unclear whether incoming President Donald J. Trump will support outgoing President Joe Biden’s plan to insure the weight loss drugs.

1 … 13 14 15 16

People

Lars Fruergaard Jørgensen

17 stories

Chiquita BrooksLaSure

14 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.